Sign In
Buy IHE
$90.02
+1.03 (+1.16%)
At Close: Jun 03, 2026
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
11:17am, Wednesday, 27'th May 2026
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?
04:19pm, Tuesday, 19'th May 2026
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every
Trump to announce discount drug pricing expansion, White House official says
12:47pm, Monday, 18'th May 2026
U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Mond
IHE: Healthcare Dashboard For May
10:42am, Saturday, 16'th May 2026
The healthcare sector is undervalued based on historical averages, especially the healthcare equipment industry. iShares U.S. Pharmaceuticals ETF offers cap-weighted exposure to U.S. pharma, with 44%
The Silver Tsunami: Healthcare ETFs to Buy Amid Aging US Demographics
11:41am, Wednesday, 13'th May 2026
ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
07:21am, Monday, 11'th May 2026
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equit
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
07:21am, Wednesday, 29'th Apr 2026
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.
Could pressure to make money faster kill the next lifesaving pill?
11:27am, Wednesday, 15'th Apr 2026
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
What Johnson & Johnson Earnings Signal for Healthcare ETFs
04:51pm, Tuesday, 14'th Apr 2026
With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in r
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
07:21am, Monday, 09'th Mar 2026
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund launched on May 1, 20
IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features
04:18pm, Friday, 27'th Feb 2026
The iShares U.S. Pharmaceuticals ETF is led by Johnson & Johnson and Eli Lilly, two stocks whose earnings per share has nearly doubled over the last twelve months. Also in IHE's top ten holdings list
3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers
03:55pm, Tuesday, 27'th Jan 2026
Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.
5 ETFs to Buy for January
01:00pm, Thursday, 08'th Jan 2026
5 ETFs to buy in January: momentum, small caps, chips, defense and healthcare shine as markets rally early in 2026 -- IWM, MTUM, SMH, XAR and IHE.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
07:21am, Wednesday, 07'th Jan 2026
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on
Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends
02:46pm, Monday, 22'nd Dec 2025
XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.
